Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Sep 30, 2025
Revenue increased sequentially and year over year, reflecting continued product demand. The quarter benefited from the company's expanding portfolio of treatments.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Revenue increased sequentially and year over year, reflecting continued product demand. The quarter benefited from the company's expanding portfolio of treatments.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.1B
Revenue reported for this quarter.
Quarter-over-quarter
+3.8%
Change from the immediately preceding quarter.
Year-over-year
+11.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$11.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $2.9B | +15.7% |
| Mar 31, 2025 | $2.8B | +3.0% |
| Jun 30, 2025 | $3B | +12.1% |
| Sep 30, 2025 | $3.1B | +11.0% |
Revenue performance
Revenue grew from the prior quarter and from the same quarter last year, driven by the company's approved therapies.
Quarterly comparison
Compared to the preceding quarter, revenue rose moderately. On a year-over-year basis, the increase was more pronounced, highlighting sustained growth.
What to watch
Monitor the trajectory of new product launches and their contribution to future revenue.